Cholangiocarcinoma (Bile Duct Cancer)

Cholangiocarcinoma affects approximately 8,000 to 10,000 individuals a year in the United States.1,2 FGFR genetic aberrations are present in about 20% of these cases.3-6 These types of aberrations include FGFR2 fusions (or translocations) in which 2 chromosomes exchange parts at the FGFR2 location resulting in a structural rearrangement.6,7

In early clinical trials, infigratinib has shown promising clinical activity in cholangiocarcinoma with FGFR2 fusions.8

The single arm, open-label, Phase 2 trial for infigratinib is being conducted in patients with previously treated, advanced cholangiocarcinoma with FGFR2 fusions.8 The trial remains open and is currently enrolling.9

FGFR=fibroblast growth factor receptor.

Learn more about this clinical trial, which is currently enrolling

In an Interim Analysis of 67 Patients With Previously Treated Cholangiocarcinoma Containing FGFR2 Fusions, Infigratinib Demonstrated8,10*:


Disease control rate (CR+PR+SD)


Best overall response


Confirmed overall response rate

6.8 Months

Median progression-free survival

  1. In patients with potential for confirmation (patients completed [or discontinued prior to] 6 cycles). Investigator confirmed.

The primary endpoint of this trial was overall response rate (CR+PR). Disease control rate, best overall response, and progression-free survival were secondary endpoints.8

In the interim analysis, the most common treatment-emergent adverse events (all grades) included hyperphosphatemia (73%), fatigue (49%), stomatitis (45%), alopecia (38%), and constipation (35%). Most adverse events were manageable with drug treatment and routine supportive care.8 The adverse events observed with infigratinib were as expected based on published data for FGFR inhibitor therapies.8,11,12

  1. The best overall response is the best response recorded from the start of treatment until the end of treatment.
  2. The overall response rate is the sum of the CR rate and the PR rate, where CR is 100% reduction in target lesion size or complete tumor disappearance and PR is a ≥30% reduction in the sum of target lesion diameter.

CR=complete response; PR=partial response; SD=stable disease.

84% Disease Control Rate With Infigratinib (N=67)8

84% disease control rate in cholangiocarcinoma with infigratinib


  1. Key statistics for bile duct cancer. American Cancer Society, 2018. Accessed November 12, 2018.
  2. Dana-Farber Cancer Institute. About biliary cancer. Accessed October 31, 2018.
  3. Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol. Published online January 17, 2018. doi:1200/PO.17.00080.
  4. Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18(11):2780-2794.
  5. Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630-1638.
  6. Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087. doi: 10.1038/ncomms7087.
  1. Griffiths AJF, Miller JH, Suzuki DT, et al. An Introduction to Genetic Analysis. 7th edition. New York: W. H. Freeman; 2000. Accessed December 10, 2018.
  2. Javle M, Kelley RK, Roychowdhury S, et al. A phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma containing FGFR2 fusions. Poster presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany.
  3. National Institutes of Health. A phase II, single arm study of BGJ398 in patients with advanced cholangiocarcinoma. Accessed October 29, 2018.
  4. Data on file. 2018. QED Therapeutics.
  5. Hollebecque A, Borad M, Sahai V, et al. Interim results of fight-202, a phase 2, open-label, multicenter study of INCB054828 in patients with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor genetic alterations. Poster presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany.
  6. Taiho Oncology. Taiho Oncology presents data on key investigational compound TAS-120 at ESMO 20th world congress on gastrointestinal cancer 2018. Published June 20, 2018. Accessed December 3, 2018.
  • Sign Up

    Stay up to date.

    Receive updates on the development of infigratinib and breaking news from QED Therapeutics.

    *Required fields.

  • Communication Agreement

    By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.

  • This field is for validation purposes and should be left unchanged.

Contact Us

75 Federal Street
San Francisco, CA 94107